Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer
Monte Rosa Therapeutics, Inc. (GLUE)
Company Research
Source: GlobeNewswire
BOSTON, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Owen Wallace, Ph.D., the Company’s Chief Scientific Officer will be departing from his position to transition to a Chief Executive Officer role at a UK-based biotechnology company. Dr. Wallace will serve as a scientific advisor to Monte Rosa, including as a member of its Scientific Advisory Board (SAB). The Company’s drug discovery organization will continue to be led by a highly accomplished team that includes Sharon Towson, Ph.D., Chief Technology Officer; John Castle, Ph.D., Chief Data and Information Officer; and Magnus Walter Ph.D., Senior Vice President, Drug Discovery. “We would like to thank Owen for his many contributions to Monte Rosa over the past three years. Owen was instrumental in the development of our QuEEN™ drug discovery engine and the advancement
Show less
Read more
Impact Snapshot
Event Time:
GLUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GLUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GLUE alerts
High impacting Monte Rosa Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
GLUE
News
- Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering [Yahoo! Finance]Yahoo! Finance
- Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public OfferingGlobeNewswire
- Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]Yahoo! Finance
- Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswire
- Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
GLUE
Earnings
- 5/9/24 - Beat
GLUE
Sec Filings
- 5/16/24 - Form 8-K
- 5/16/24 - Form 424B5
- 5/15/24 - Form 424B5
- GLUE's page on the SEC website